COMPANY OVERVIEW

Siragen Pharmaceuticals is a new biotechnology company developing small molecules aimed at aging and neurodegenerative disorders. Siragen targets signaling mechanisms crucial for the initial manifestation of disease processes. Using a radical new platform, Siragen discovers and develops drugs that will prevent and slow the progression of Alzheimer’s disease. “Siragen’s small molecule products will be for the brain what statins are for the heart”. Based in San Diego, California, Siragen is a spin-off from Neurogeneration Inc. The co-founders are Michel Levesque, MD, entrepreneur and neuroscientist, and Mohamedi Kagalwala, PhD MBA, biochemist and neurobiologist. Our scientific advisory board consists of prominent scientists, entrepreneurs, and experts from the pharma industry providing specific domain expertise to aggressively execute different stages of Siragen’s programs.

PRODUCT PIPELINE

OUR BREAKTHROUGH SOLUTION

Siragen’s unique drug discovery efforts have been focused on a major molecular enzyme central to both intracellular calcium dyshomeostasis and Tau accumulation. Siragen’s novel target is central to pathways that trigger synaptic dysfunction leading to pathological landmarks of neuro-degenerative disorders. Siragen’s small molecules have been modeled based on intrasteric regulation using a novel structure-guided design, enhancing drastically the specificity, and preventing action on downstream kinases. Inhibiting this target modulates upstream events prior to the onset of pathological changes of Tau hyperphosphorylation, soluble amyloid oligomers, aberrant autophagy, synaptic dysfunction, synapse loss and cell death. Siragen’s inhibitors are at the lead optimization stage for Alzheimer’s disease. Siragen’s novel drug design platform is also a paradigm shift for creating additional kinase inhibitors by deactivating regulatory domain. Siragen’s new prototypes of kinase inhibitors can be applicable to a number of diseases in which auto-inhibitory dysfunction is the major mechanism of pathophysiology. At least three classes of diseases have been reported to be causally associated with aberrant kinase activity: central nervous system disorders (depression, schizophrenia), metabolic disorders (obesity and diabetes) and cancers (prostate, liver).
STRATEGIC DEVELOPMENT

Siragen’s current development programs are focused on 1) lead optimization 2) non-clinical trials on identified compounds 3) IND enabling studies. The Company aims to develop its pipeline of novel molecules to clinical proof of concept and either exit or partner with pharma industry leaders for clinical development and commercialization. The Company is raising funds to support its drug development, chemical formulation, pharmacokinetics, non-clinical, and IND enabling studies. Siragen plans to collaborate with well-known experts in the field of neurodegeneration and with strategic leaders in large research organizations and pharmaceutical companies.

FINANCIALS

Siragen is raising $3 million pre-A to accomplish the following objectives:

1. Crystal structure guided medicinal Chemistry optimization of compounds
2. In vivo pharmacology (PK/ADME/initial toxicology)
3. Non-clinical Proof of concept and identify a pre-IND asset
4. Selective addition to its scientific and corporate team

MANAGEMENT TEAM

Michel F Levesque, MD, Co-Founder
Mohamedi Kagalwala, PhD MBA, Co-Founder
Patricia Eastman, VP, Corporate Development

Eliezer Masliah, MD, Dept. of Neuroscience, UCSD
Anthony Means, PhD, Baylor College of Medicine

COLLABORATION

Salk Institute of Biological studies, La Jolla, CA
UCSD Dept. of Neuroscience, San Diego, CA
UCLA Brain Research Institute, Los Angeles,

FORWARD LOOKING STATEMENT Certain statements included in this fact sheet may constitute “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Siragen Pharmaceuticals, Inc. (“Siragen” or “Company”), or industry results, to be materially different from any future results.